Alloy (Pharmaceuticals) key facts
- Developer of women's health care products intended to promote wellness and manage menopause effectively.
- Alloy (Pharmaceuticals)’s last known valuation is $160.0M.
- It has raised $18.3M; the latest was Later Stage VC ($15.8M) in Nov 2024.
- Notable investors include Matter (Consulting Services (B2B)), Kinled Holding, Amboy Street Ventures, Seven Hound Ventures, Emmeline Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Alloy (Pharmaceuticals): the Monday email on marks, rounds and moves
Alloy (Pharmaceuticals) funding rounds
No funding rounds for Alloy (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Alloy (Pharmaceuticals) valuation
Alloy (Pharmaceuticals)'s last known valuation is $160 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Alloy (Pharmaceuticals) investors
7 investors are on record for Alloy (Pharmaceuticals), including Matter (Consulting Services (B2B)), Kinled Holding, Amboy Street Ventures and Seven Hound Ventures.
About Alloy (Pharmaceuticals)
Developer of women's health care products intended to promote wellness and manage menopause effectively. The company's products include a line of natural items created for conditions like menopause, osteoporosis, and weight gain, enabling women to live a healthy and long life.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 45
- Website
- myalloy.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Alloy (Pharmaceuticals)’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.